HAE Haemonetics Earnings and EPS analysis

EPS in 2026 (TTM): $2.06

Last Report Period Date: Mar 28, 2026

As of July 2026, HAE's trailing twelve months (TTM) EPS stands at $2.06, according to the latest financial reports. In 2026, the company recorded an earnings per share (EPS) of $2.06, which represents a decrease compared to its EPS of $3.33 in 2025. HAE reported an EPS of -$0.41 for the quarterly report ending on Mar 28, 2026.

For 2026, Haemonetics's EPS was $2.06, a decrease of 38.1% from $3.33 in 2025. For the quarter ending Mar 28, 2026, the EPS was -$0.41, showing a 135% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $2.06. In 2025, the annual EPS was $3.33, showing an increase of 43.5% from 2024.

Over the last 12 months, Haemonetics has registered an EPS growth of -135% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -3.2% per year. Over the last 5 years, the company had an average EPS growth rate of 5.6%.